Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02138214 · ClinicalTrials.gov registry record · Phase 2

Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer

A Phase 2 study of Stage I Papillary Thyroid Cancer and Stage II Papillary Thyroid Cancer, sponsored by University of Wisconsin, Madison.

Completed
Registry status
Phase 2
Development phase
117
Enrollment target
1
Study location

NCT02138214: Completed Phase 2 study of Stage I Papillary Thyroid Cancer and Stage II Papillary Thyroid Cancer, sponsored by University of Wisconsin, Madison.

NCT02138214 is a Phase 2 study of Stage I Papillary Thyroid Cancer and Stage II Papillary Thyroid Cancer that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 117 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (12% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02138214, a Phase 2 study of Stage I Papillary Thyroid Cancer and Stage II Papillary Thyroid Cancer, has completed, sponsored by University of Wisconsin, Madison.

COMPLETED
Registry status
Phase 2
Development phase
117 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies how well thyroid gland removal with or without central lymph node dissection works in treating patients with thyroid cancer or suspected thyroid cancer that has not spread to the lymph nodes (randomized into Arms I and II). Arms I and II are compared to a standard of care (SOC) Arm III to enable comparison of quality of life among various surgical treatments. Currently, the standard treatment for thyroid cancer is total thyroidectomy, or complete removal of the thyroid. The lymph nodes in the central part of the neck may also be surgically removed, called central lymph node dissection. Prophylactic removal of the lymph nodes may increase the risk of life-threatening complications, and may reduce post-surgery quality of life. It may also prevent the cancer from returning and reduce the need for additional surgery. It is not yet known whether recurrence rates and complication levels are lower after thyroid gland removal alone or with central lymph node dissection.

Primary Outcome

Rate of transient hypoparathyroidism will be assessed in terms of percentage of participants with day 1 serum PTH level of \< 10 pg/ml.

Interventions

  • PROCEDURE Thyroidectomy
  • PROCEDURE entral lymph node dissection (CLND)
  • OTHER Quality-of-life assessment

Study Locations (1)

Wisconsin

  • University of Wisconsin - Madison

Trial Details

FieldValue
Enrollment Target 117 participants
Start Date 2014-06-06
Est. Completion 2020-10-26
Phase Phase 2
University of Wisconsin, Madison

1,039 total trials

What the finished NCT02138214 record still lists

NCT02138214 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (12% lower).

The record links to 3 conditions, with Stage I Papillary Thyroid Cancer appearing as the primary indexed condition, and to 3 interventions - of which Thyroidectomy is the first listed.

NCT02138214 reports a single indexed study location in Wisconsin.

Frequently Asked Questions

What is clinical trial NCT02138214 about?

NCT02138214 is a clinical study titled "Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer". This phase II trial studies how well thyroid gland removal with or without central lymph node dissection works in treating patients with thyroid cancer or suspected thyroid cancer that has not spread to the lymph nodes (randomized into Arms I and II). Arms I and II are compared to a standard of care...

What is the current status of trial NCT02138214?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 117 participants. The study started on 2014-06-06. Estimated completion is 2020-10-26.

What conditions does trial NCT02138214 study?

This clinical trial studies the following conditions: Stage I Papillary Thyroid Cancer, Stage II Papillary Thyroid Cancer, Stage III Papillary Thyroid Cancer.

What interventions are being tested in trial NCT02138214?

The interventions under investigation include: Thyroidectomy (PROCEDURE), entral lymph node dissection (CLND) (PROCEDURE), Quality-of-life assessment (OTHER).

Who is sponsoring clinical trial NCT02138214?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02138214 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT02138214's enrollment target sits among peer trials

117 623rd of 2000 higher than 1,378 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03539822 · 117 participants · Phase 1

    Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

  • NCT03786692 · 117 participants · Phase 2

    Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

  • NCT04479696 · 117 participants · NA

    Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors

  • NCT04940585 · 117 participants · NA

    ROSE in Sunset Park

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02138214, the US trial registry maintained by the National Library of Medicine. NCT02138214 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.